219989-24-9

Basic information

• Product Name: 5,6,7,8-TETRAHYDRO-4H-FURO[3,2-B]AZEPINE
• Synonyms: 5,6,7,8-TETRAHYDRO-4H-FURO[3,2-B]AZEPINE
• CAS NO: 219989-24-9
• Molecular Formula: C₈H₁₁NO
• Molecular Weight: 137.18
• Mol File: 219989-24-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5,6,7,8-TETRAHYDRO-4H-FURO[3,2-B]AZEPINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8-TETRAHYDRO-4H-FURO[3,2-B]AZEPINE(219989-24-9)
• EPA Substance Registry System: 5,6,7,8-TETRAHYDRO-4H-FURO[3,2-B]AZEPINE(219989-24-9)

Safety Data

• Hazardous Substances Data: 219989-24-9(Hazardous Substances Data)

Usage

General Description

5,6,7,8-Tetrahydro-4H-furo[3,2-b]azepine, also known as tetrahydrofuroazepine, is a chemical compound with a bicyclic structure containing a furo[3,2-b]azepine ring system. It is a colorless liquid with a molecular formula C9H13NO and a molecular weight of 151.21 g/mol. Tetrahydrofuroazepine has been studied for its potential pharmaceutical properties, including its effects on the central nervous system and its potential as a ligand for specific receptors. It is also known for its potential application in organic synthesis as a building block for the production of other chemical compounds. Further research is ongoing to explore the potential uses and properties of this compound.

Upstream product

• 16806-93-2 4-oxo-4,5,6,7-tetrahydrobenzofuran 
• 61190-46-3 6,7-dihydro-1-benzofuran-4(5H)-one oxime 
• 180339-33-7 4,5,6,7-tetrahydrobenzo[b]furan-4-one (Z)-oxime 

Downstream Products

• 186808-27-5 (4-Nitro-phenyl)-(5,6,7,8-tetrahydro-furo[3,2-b]azepin-4-yl)-methanone 

Relevant articles and documents

Synthesis and Structure-Activity Relationships of 5,6,7,8-Tetrahydro-4H-thieno[3,2-b]azepine Derivatives: Novel Arginine Vasopressin Antagonists

A variety of novel heterocyclic compounds having thienoazepine, pyrroloazepine, furoazepine, and thienodiazepine skeletons were synthesized, most of which exhibited potent antagonism of [3H]-AVP specific binding in assays using rat liver (V1), rat kidney (V2), human platelet plasma membranes, and recombinant human CHO cells (V2), as well as antagonizing AVP-induced hypertension in rats (V1, intravenous) and showing a diuretic effect in rats (V2, oral). By detailed studies of the structure-activity relationships of these compounds, the thienoazepine derivative 1 was found to be a very potent combined V1 and V2 antagonist. After further pharmacological and toxicological evaluation as well as physical properties, the hydrochloride 2 (JTV-605) of compound 1 was selected for clinical studies as a potent AVP antagonist with a long duration of action.